RegeneRx Biopharmaceuticals, Inc.
RGRX
$0.0002
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 42.22% | 2.67% | 2.67% |
| SG&A Expenses | -10.72% | -15.20% | -27.27% | 75.24% | 14.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.72% | -15.20% | -28.24% | 74.98% | 13.94% |
| Operating Income | 11.31% | 16.00% | 29.58% | -80.57% | -14.83% |
| Income Before Tax | 9.17% | 13.06% | 14.73% | -61.25% | -11.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.17% | 13.06% | 14.73% | -61.25% | -11.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.17% | 13.06% | 14.73% | -61.25% | -11.69% |
| EBIT | 11.31% | 16.00% | 29.58% | -80.57% | -14.83% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.17% | 13.03% | 14.79% | -50.08% | -3.87% |
| Normalized Basic EPS | 9.15% | 13.03% | 24.50% | -50.06% | -3.88% |
| EPS Diluted | 9.17% | 18.46% | 14.79% | -50.08% | -3.87% |
| Normalized Diluted EPS | 9.15% | 13.03% | 24.50% | -50.06% | -3.88% |
| Average Basic Shares Outstanding | 0.00% | -0.03% | 0.05% | 7.40% | 7.51% |
| Average Diluted Shares Outstanding | 0.00% | -0.03% | 0.05% | 7.40% | 7.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |